Aimmune Therapeutics, Inc. has filed a Form S-1 with the U.S. Securities and Exchange Commission (SEC) proposing an initial public offering (IPO) of its common stock. This means that the allergy research and development program may become traded on the market.
Aimmune Therapeutics is a clinical-stage bipharmaceutical company developing treatments for peanut and other food allergies. Their oral immunotherapy system, CODIT, recently completed a Phase 2 clinical trial.
The symbol AIMT is aimed for the NASDAQ Global Market and could win approval as early as this year.
The SEC must approve the stock offering and the number of shares and price range for them has not been set. Managers of the IPO and offerings are BofA Merrill Lynch, Credit Suisse and Piiper Jaffray. The initial offering will be a prospectus, if approved.
Investors should be aware that the efficacy and safety of the CODIT product has not been verified by the Food and Drug Administration and trials are ongoing. The SEC has not approved the stock offering and this website does not endorse AIMT in any way. This information is being published as news only.
More information and queries can be had through the link below.